Submit your email to push it up the queue
SmithKline Beecham Limited, commonly referred to as SB or GlaxoSmithKline (GSK), is a prominent player in the global pharmaceutical and healthcare industry. Headquartered in Great Britain, the company has a significant operational presence across Europe, North America, and Asia. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since achieved numerous milestones, including advancements in vaccine development and consumer healthcare products. GSK's core offerings encompass prescription medicines, vaccines, and consumer health products, distinguished by their commitment to innovation and quality. The company is renowned for its research-driven approach, particularly in areas such as respiratory health, HIV, and oncology. With a strong market position, GSK consistently ranks among the top pharmaceutical companies globally, recognised for its contributions to public health and commitment to sustainability.
How does SmithKline Beecham Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
SmithKline Beecham Limited's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SmithKline Beecham Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of GSK plc, which cascades its climate commitments and initiatives down to SmithKline Beecham Limited. GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for Scope 1 and 2 emissions, and by 2045 for Scope 3 emissions. The specific reduction targets and achievements of GSK plc are inherited by SmithKline Beecham Limited, reflecting the company's commitment to sustainability and climate action. As a subsidiary, SmithKline Beecham Limited aligns with GSK plc's participation in various climate initiatives, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on sourcing 100% renewable electricity. These commitments underscore the company's dedication to addressing climate change and reducing its carbon footprint in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SmithKline Beecham Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.